CellCentric announces oversubscribed $220 million Series D financing
CellCentric, a clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma, today announced the completion of an oversubscribed $220 million Series D financing. The financing was led by specialist investor Venrock Healthcare Capital Partners, with participation from a strong syndicate of new and existing investors.
Proceeds will support the advancement of inobrodib through pivotal clinical development studies, including continued enrollment of the company’s recently initiated Phase 2 DOMMINO-1 study in the UK and US and initiation of the global Phase 3 DOMMINO-2 trial in the second half of 2026. Capital raised will also fund expansion of inobrodib into additional combination and maintenance treatment settings.
Will West, Ph.D., CEO of CellCentric, said:
“We are thrilled to have the support of top-tier investors who believe in inobrodib’s potential to address a critical need in multiple myeloma, notably after bispecific T cell engager or anti-BCMA therapies. This is a significant and growing unmet need. Inobrodib is a new modality and a potential fresh option for patients that is orally administered. In combination with pomalidomide and dexamethasone as InoPd, we have demonstrated deep responses in heavily pretreated relapsed or refractory multiple myeloma patients. Fueled by this funding, we are well positioned to complete registration enabling studies for the all-oral triplet and advance our progress toward delivering a transformative treatment.”
Phase 2 dose-optimization data shared in December 2025 at ASH demonstrated that 20 mg inobrodib in combination with standard doses of pomalidomide and dexamethasone (InoPd) represents at least a two-fold increase in response rates compared to historic alternative therapies in patients with relapsed or refractory multiple myeloma (RRMM) who were heavily pretreated (median five lines of prior therapy).
Ken Greenberg, M.D., Partner at Venrock, said:
What stands out with inobrodib is the consistency of clinical activity alongside a manageable safety profile in a heavily pretreated population. An oral drug with a novel, additive approach could play an important role in later-line therapy, as well as across the treatment landscape in multiple myeloma. We are excited to support its advancement into pivotal studies.
